Exact Sciences Corp (EXAS) Dividend History

Exact Sciences Corp (EXAS) is a molecular diagnostics company focused on developing and commercializing innovative tests for cancer detection and prevention. The company's flagship product, Cologuard, is a non-invasive stool-based screening test for colorectal cancer. Exact Sciences also invests in advancing genomics and liquid biopsy technologies to improve early cancer detection and patient management.

5505 Endeavor Lane, Madison, WI, 53719
Phone: 608-284-5700
Website: https://www.exactsciences.com

Dividend History

Exact Sciences Corp currently does not pay dividends

Company News

Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape

The report highlights the rapid advancements in the molecular diagnostics for cancer market, driven by trends like personalized medicine, pharmacogenomics, and liquid biopsy. It profiles over 140 companies and provides extensive data and forecasts to aid decision-making in this evolving global market.

GlobeNewswire Inc.

Featured Companies: A ABT GH ILMN NTRA QGEN TMO TXG
US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks

U.S. stocks may open sluggishly on Tuesday as President-elect Trump threatens tariffs on Canada and Mexico. However, analysts remain optimistic about AI-linked sectors.

Benzinga

Featured Companies: BBY BLBD QQQ RIVN SMTC SPY WWD
Can This Beaten-Down Cathie Wood Stock Bounce Back?

Exact Sciences' new Cologuard Plus test has received FDA approval and outperforms a competing product from Guardant Health. This could help Exact Sciences remain competitive in the colorectal cancer screening market and improve its profitability, making the stock a promising investment for patient investors.

The Motley Fool

Featured Companies: GH
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

Zacks Investment Research

Featured Companies: LLY NKTR TRDA
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230. Click here for a detailed analysis.

Seeking Alpha

Featured Companies: ARKB ARKF ARKG ARKK ARKQ ARKW ARKX BEAM COIN CRSP DKNG DNA HOOD META NTLA PATH PD PINS PLTR RBLX ROKU RXRX SHOP SQ TDOC TER TSLA TTD TWLO TXG U VCYT ZM

Page data last updated 07/23/2025 09:56:35 UTC